Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Inclusion Criteria:

Common to both disease cohorts:

   - Proteinuria ≥1 (gram [g]/day or g/g)

   - Vaccinated against meningococcal infection

   - Vaccinated for Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae
   according to national/local regulatory requirements

For LN cohort:

   - Diagnosis of active focal or diffuse proliferative LN Class III or IV

   - Clinically active LN, requiring/receiving immunosuppression induction treatment

For IgAN cohort:

   - Diagnosis of primary IgAN

   - Compliance with stable and optimal dose of renin-angiotensin system inhibitor
   treatment for ≥ 3 months

Exclusion Criteria:

Common to both disease cohorts:

   - eGFR < 30 milliliters/minute/1.73 meters squared

   - Previously received a complement inhibitor (for example, eculizumab)

   - Concomitant significant renal disease other than LN or IgAN

   - History of other solid organ or bone marrow transplant

   - Uncontrolled hypertension

For IgAN cohort:

   - Diagnosis of rapid progressive glomerulonephritis

   - Prednisone or prednisone equivalent > 20 milligram (mg) per day for > 14 consecutive
   days or any other immunosuppression within 6 months